Conference Proceedings

Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction

Peter Mollee, Stephen Boyle, Cameron Wellard, Elizabeth Moore, Hilary Blacklock, Simon J Harrison, P Joy Ho, Jay Hocking, Zoe McQuilten, Hang Quach, Ruth Spearing, Erica Wood, Andrew Spencer

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | CIG MEDIA GROUP, LP | Published : 2019